Ironwood Pharmaceuticals (IRWD) Q2 2026 earnings summary

Executive summary

• Q2 2026 LINZESS U.S. net sales reached $282.3 million, up 14% year-over-year, with year-to-date sales at $555 million, up 44% year-over-year, driven by demand growth and improved net price.

• Full-year 2026 guidance for LINZESS U.S. net sales raised to $1.15–$1.2 billion, representing over 30% year-over-year growth; total revenue guidance increased to $460–$485 million and adjusted EBITDA to over $310 million.

• FDA approved LINZESS for functional constipation in pediatric patients aged two and older, expanding its market and making it the first and only Rx for this indication.

• Apraglutide advanced with the initiation of the confirmatory Phase III STARS-2 trial for short bowel syndrome with intestinal failure.

• Q2 2026 GAAP net income was $51.3 million and adjusted EBITDA was $83 million.

Financial highlights

• Q2 2026 total revenue was $113 million, up from $85.2 million in Q2 2025, primarily from U.S. LINZESS collaboration revenue.

• GAAP net income for Q2 2026 was $51.3 million ($0.31/share basic and diluted); adjusted EBITDA was $83 million.

• Year-to-date net sales reached $555 million, up 44% year-over-year.

• Ended Q2 2026 with $79.1 million in cash and $113 million in collaboration receivables.

• $200 million convertible notes repaid at maturity using cash on hand.

Outlook and guidance

• LINZESS U.S. net sales guidance increased to $1.15–$1.2 billion for 2026, over 30% growth year-over-year; total revenue guidance raised to $460–$485 million; adjusted EBITDA expected to exceed $310 million.

• Expect mid-single-digit prescription demand growth for LINZESS for the full year.

• Guidance assumes continued demand growth and stable net pricing; potential variability from market or regulatory changes.

• Expect to end 2026 with less than $300 million gross debt and gross leverage below 1x.

• Cash, expected operating inflows, and borrowing capacity are anticipated to meet operating needs for at least the next twelve months.